cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator

(2018) Paul W. Armstrong et al.   JACC-Heart Failure

Identification and quantification of protein S -nitrosation by nitrite in the mouse heart during ischemia

(2017) Edward T. Chouchani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure

(2017) Markus Follmann et al.   JOURNAL OF MEDICINAL CHEMISTRY

Succinate metabolism: a new therapeutic target for myocardial reperfusion injury

(2016) Victoria R. Pell et al.   CARDIOVASCULAR RESEARCH

Role of atrial natriuretic peptide in ischemic preconditioning–induced cardioprotection in the diabetic rat heart

(2016) Kali Charan et al.   JOURNAL OF SURGICAL RESEARCH

The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism

(2015) Javier Inserte et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction

(2015) Mihai Gheorghiade et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease

(2015) Dong I. Lee et al.   NATURE

PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer

(2015) Anindita Das et al.   PHARMACOLOGY & THERAPEUTICS

Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition

(2014) Daniela Fraccarollo et al.   BASIC RESEARCH IN CARDIOLOGY

Delayed phospholamban phosphorylation in post-conditioned heart favours Ca2+ normalization and contributes to protection

(2014) Javier Inserte et al.   CARDIOVASCULAR RESEARCH

Circulating Nitrite Contributes to Cardioprotection by Remote Ischemic Preconditioning

(2014) Tienush Rassaf et al.   CIRCULATION RESEARCH

Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

(2014) John J. V. McMurray et al.   EUROPEAN JOURNAL OF HEART FAILURE

Mitochondria selectiveS-nitrosation by mitochondria-targetedS-nitrosothiol protects against post-infarct heart failure in mouse hearts

(2014) Carmen Methner et al.   EUROPEAN JOURNAL OF HEART FAILURE

PARADIGM-HF — The Experts' Discussion

(2014) Mariell Jessup et al.   NEW ENGLAND JOURNAL OF MEDICINE

Riociguat Reduces Infarct Size and Post-Infarct Heart Failure in Mouse Hearts: Insights from MRI/PET Imaging

(2014) Carmen Methner et al.   PLoS One

Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond

(2014) Robert Lukowski et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size

(2013) Justin S. Bice et al.   CARDIOVASCULAR RESEARCH

Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction

(2013) Margaret M. Redfield et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I

(2013) Edward T Chouchani et al.   NATURE MEDICINE

Nitrite Signaling in Pulmonary Hypertension: Mechanisms of Bioactivation, Signaling, and Therapeutics

(2012) Marta Bueno et al.   ANTIOXIDANTS & REDOX SIGNALING

Nitric Oxide Synthases in Heart Failure

(2012) Ricardo Carnicer et al.   ANTIOXIDANTS & REDOX SIGNALING

Essential role of nitric oxide in acute ischemic preconditioning: S-Nitros(yl)ation versus sGC/cGMP/PKG signaling?

(2012) Junhui Sun et al.   FREE RADICAL BIOLOGY AND MEDICINE

Differential Expression of PDE5 in Failing and Nonfailing Human Myocardium

(2011) Xiaoyin Shan et al.   Circulation-Heart Failure

The cardio-protective properties of NCX-6550, a nitric oxide donating pravastatin, in the mouse

(2010) Clara Di Filippo et al.   MICROCIRCULATION

Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure

(2010) Andreas Schäfer et al.   PHARMACOLOGICAL RESEARCH

Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice

(2009) Peter Pokreisz et al.   CIRCULATION

Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G-Dependent Generation of Hydrogen Sulfide

(2009) F. N. Salloum et al.   CIRCULATION

BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts

(2009) T. Krieg et al.   EUROPEAN HEART JOURNAL

Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics

(2009) Emily J. Tsai et al.   PHARMACOLOGY & THERAPEUTICS

Spontaneous Myocardial Infarction in Mice Lacking All Nitric Oxide Synthase Isoforms

(2008) Sei Nakata et al.   CIRCULATION

Cardioprotection

(2008) Gerd Heusch et al.   CIRCULATION

Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3β

(2008) Anindita Das et al.   JOURNAL OF BIOLOGICAL CHEMISTRY